I wouldn't pay much heed to Mr. Schoenebaum who stated that MRK can finish their PH3 trials in 6 months. lol.
Scheoenbaum also said MRK could launch its HCV regimen approximately 6 months after ABBV/ENTA (which would require building a time machine, LOL) and he was taken to task on Twitter for making such an assertion. Still, Schoenebaum is one of the better sell-side biotech analysts, IMO; everyone is entitled to an occasional lapse.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”